摘要
目的 评价五水头孢唑林钠（抗生素）治疗轻、中度急性下呼吸道细菌性感染的疗效与安全性.方法 用多中心单盲随机对照试验设计,随机分为3组：五水头孢唑林钠组34例,头孢唑林钠组33例,头孢曲松钠组36例,3组的用量、用法、疗程相同,每日2次,每次静滴2 g,疗程7～14天.结果 疗程结束时,五水头孢唑林钠与头孢唑林钠、头孢曲松钠痊愈率和有效率分别为76.47%,66.66%,30.56%与97.06%,87.88%,52.78%;药物不良反应发生率分别为2.86%,2.94%,5.56%.结论 五水头孢唑林钠治疗轻、中度急性下呼吸道细菌性感染,疗效确切,安全性较好.
Objective To evaluate the climical efficacy and safety of domestic cefazolin sodium pentahydrate （ trial ） vs cefazolin （ control Ⅰ ） and ceftriaxon （ control Ⅱ） for the treatment of acute bacterial infections. Methods A multicenter, single- blind, randomized clinical trail was carried. Three group were administered infravenously at a dose of 2 g , bid, for 7 to 14 days. A total of 103 patients in three groups（trial：33, control Ⅰ：34;control Ⅱ：36） with respiratory tract infections were enrolled in the study. Results At the end of the treatment, the cure rate and effective rate were 76.47% （trial） ,66.66% （control Ⅰ） ,30.56% （control Ⅱ） ; clinical efficacy rate were 97.06% （trial）, 87.88% （control Ⅰ） 52.78% （control Ⅱ） respectively. The incidence of adverse reaction were 2.86% ,2.94% ,5.56% ,respectively. Conclusion The cefazolin sodium pentahydrate had an excellent clinical efficacy and good safety profile in treating patients with bacterial infections.
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2006年第5期326-328,共3页
The Chinese Journal of Clinical Pharmacology
